In the 1980s, 2 milestones for treating prostate cancer occurred. The first was the development, by T. Ming Chu and his colleagues at Roswell Park Cancer Institute, of prostate-specific antigen (PSA) testing for monitoring treatment (FDA-approved 1986) and then for early detection (FDA-approved 1994). The second was the development, by Patrick Walsh and his colleagues at Johns Hopkins Hospital, of anatomic radical prostatectomy that made surgical treatment of clinically localized prostate cancer safe. The 1990s saw the development of—and demonstration of a survival benefit from—taxotere-based chemotherapy for advanced prostate cancer and the development of conformal external beam radiation therapy that allows safer delivery of doses of sufficient intensity to generate meaningful control of clinically localized prostate cancer. Progress in these 2 decades set the table for an explosion of progress over the past 10 years.
Andriole GL, Crawford ED, Grubb RL III. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–1319.
Schroder FH, Hugosson J, Roobol MJ. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–1328.
U.S. Prevntative Services Task Force: Screening for Prostate Cancer. USPSTF Program Office; Rockville, MD: August 2008 (current as of December 2011). Available at http://www.uspreventiveservicestaskforce.org/uspstf/uspsprca.htm. Accessed January 17, 2012.
Drazer MW, Huo D, Schonberg MA. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol 2011;29:1736–1743.
Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA 2006;296:2336–2342.
Hugosson J, Carlsson S, Aus G. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725–732.
Bartsch G, Horninger W, Klocker H. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008;101:809–816.
Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8:268–278.
Menon M, Hemal AK. Vattikuti Institute prostatectomy: a technique of robotic radical prostatectomy: experience in more than 1000 cases. J Endourol 2004;18:611–619; discussion, 619.
Miller DC, Gruber SB, Hollenbeck BK. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134–1141.
Tosoian JJ, Trock BJ, Landis P. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185–2190.
Dall’Era MA, Konety BR, Cowan JE. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008;112:2664–2670.
Attard G, Reid AH, A’Hern R. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742–3748.
Tran C, Ouk S, Clegg NJ. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787–790.
Smith JC, Bennett S, Evans LM. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:4261–4267.
Fizazi K, Carducci M, Smith M. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813–822.
Kantoff PW, Higano CS, Shore ND. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411–422.
de Bono JS, Oudard S, Ozguroglu M. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147–1154.